Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 249-047-0 | CAS number: 28473-19-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 7.9 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- By inhalation
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 50
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 392.6 mg/m³
- Explanation for the modification of the dose descriptor starting point:
- Route to route extrapolation was necessary.
- AF for dose response relationship:
- 1
- Justification:
- Default ECHA AF; NOAEL derived from an OECD Guideline 90-day oral toxicity study. No significant effects were observed in rats dosed with 300 mg/kg/day.
- AF for differences in duration of exposure:
- 2
- Justification:
- Default ECHA AF for subchronic (90-day) to chronic extrapolation.
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Default ECHA AF for rat for toxicokinetic differences in metabolic rate (allometric scaling) not applicable.
- AF for other interspecies differences:
- 2.5
- Justification:
- Default ECHA AF for remaining toxicokinetic differences (not related to metabolic rate) and toxicodynamic differences.
- AF for intraspecies differences:
- 5
- Justification:
- Default ECHA AF for (healthy) worker.
- AF for the quality of the whole database:
- 2
- Justification:
- The available data on DIDS and good read-across compounds are adequate to derive the DNEL. DIDS is a simple diester that rapidly hydrolyses to a fatty acid and alcohol (as also suggested by the results of a ready biodegradability test). Its toxicological characteristics are well understood and accepted to be of low concern. Properties can therefore be predicted with reasonable confidence.
- AF for remaining uncertainties:
- 1
- Justification:
- No further uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 15 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- By inhalation
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 200
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 3 000 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- As no data on effects of repeated dermal exposure to DIDS in humans or laboratory animals are available, route-to-route extrapolation to calculate a DNEL for such effects from repeated dose oral toxicity study was considered a suitable alternative.
- AF for dose response relationship:
- 1
- Justification:
- Default ECHA AF; NOAEL from an OECD Guideline 90-day oral toxicity study. No significant effects were observed in rats dosed with 300 mg/kg/day.mg/kg/day DIDS.
- AF for differences in duration of exposure:
- 2
- Justification:
- Default ECHA AF for subchronic (90-day) to chronic extrapolation.
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- Default ECHA AF for rat for toxicokinetic differences in metabolic rate (allometric scaling).
- AF for other interspecies differences:
- 2.5
- Justification:
- Default ECHA AF for remaining toxicokinetic differences (not related to metabolic rate) and toxicodynamic differences.
- AF for intraspecies differences:
- 5
- Justification:
- Default ECHA AF for (healthy) worker.
- AF for the quality of the whole database:
- 2
- Justification:
- The available data on DIDS and good read-across compounds are adequate to derive the DNEL. DIDS is a simple diester that rapidly hydrolyses to a fatty acid and alcohol (as also suggested by the results of a ready biodegradability test). Its toxicological characteristics are well understood and accepted to be of low concern. Properties can therefore be predicted with reasonable confidence.
- AF for remaining uncertainties:
- 1
- Justification:
- No further uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
Acute toxicity
No acute toxicity data are available on DIDS in humans or laboratory animals.
Limited oral and inhalation, and reliable dermal, studies on good read-across substances (DIDA and DOS/DEHS) generally show low acute toxicity.
The weight of the evidence does not indicate that DIDS should be classified as acutely toxic via the oral, dermal or inhalation routes of exposure under the EU DSD or CLP regulations.
DNELs for acute toxicity should be derived if an acute toxicity hazard, leading to classification and labelling (e.g. under EU CLP regulations) has been identified and there is a potential for high peak exposures (this is only usually relevant for inhalation exposures). This is not the case for DIDS. Consequently, no worker-DNELs for acute toxicity have been calculated.
Irritation/corrosivity
No skin irritation/corrosivity data are available on DIDS in humans or laboratory animals.
DIDA and DEHS were not irritating in reliablein vitroand laboratory animal studies, and a non-guideline study on DEHS did not indicate a potential for respiratory irritation.
The weight-of-evidence does not indicate that DIDS should be classified as a skin, eye or respiratory irritant under EU CLP regulations. Consequently, no worker-DNELs for irritation/corrosivity have been calculated.
Sensitisation
No skin sensitisation data are available on DIDS in humans or laboratory animals.
In limited studies on humans and laboratory animals, DIDS and DOS did not demonstrate a strong skin sensitising potential.
Although no relevant studies are available, DIDS is not expected to be a respiratory sensitiser, based on its predicted lack of skin sensitising potential and the limited possibility of respiratory exposure (low volatility) under normal conditions of use.
The weight-of-evidence does not indicate that DIDS should be classified as a skin or respiratory sensitiser under EU r CLP regulations. Consequently, no worker-DNELs for skin or respiratory sensitisation have been calculated.
Oral DNEL (repeated dose toxicity)
Not considered applicable for workers.
Inhalation DNEL (repeated dose toxicity)
Dose descriptor
There are no data available in humans or laboratory animals relating to repeated inhalation exposure of DIDS.
Kidney toxicity was seen in male rats receiving 1000 mg/kg/day in an OECD Guideline 90-day toxicity study on DIDS, but not female rats. No significant effects were seen in either sex receiving 300 mg/kg/day DIDS.
Mode-of-action
DIDS is considered to have only threshold effects, as there is no convincing evidence that it possesses genotoxic potential. The lesion seen in male rat kidneys has the characteristics ofhyaline dropletnephropathy is most likely due to ana2mglobulin mode of action and is not relevant for humans. Immunohistopathology has not been carried out on the male rat kidney tissues so thea2mglobulin mode of action cannot be confirmed. As a consequence, the most conservative approach to risk assessment has been adopted by selecting the NOAEL in male rats as the starting point (300 mg/kg/day)
Modification of starting point
The corrected inhalation NOAEC for DIDS =
300 * (1/ sRV(a) *ABS oral-rat / ABS inhal-human (b) * 0.67 (c))
Where: (a) Standard respiratory volume (sRV) rat = 0.384 m3/kg
(b) For oral route based on toxicokinetics data on DOA (EC number: 203-090-1 CAS number: 103-23-1)
ABS oral-rat = 75 % and ABS inhal-human = 100 %
(c) correction for worker respiratory volume (conservative default for route to route)
= 300*1/0.384*75/100*0.67 = 392.6 mg/m3
In the absence of any data to the contrary, the same bioavailability is assumed for humans and laboratory animals.
Workers are assumed to be exposed for 8 hr/day.
ECHA AFs for workers – inhalation DNEL (repeated dose toxicity)
Uncertainty |
AF |
Justification for AF |
|
Interspecies differences |
1 |
Default ECHA AF for rat for toxicokinetic differences in metabolic rate (allometric scaling) not applicable. |
|
2.5 |
Default ECHA AF for remaining toxicokinetic differences (not related to metabolic rate) and toxicodynamic differences. |
||
Intraspecies differences |
5 |
Default ECHA AF for (healthy) worker. |
|
Differences in duration of exposure |
2 |
Default ECHA AF for sub-chronic (90-day) to chronic extrapolation. |
|
Dose response and endpoint specific/severity issues |
1 |
Default ECHA AF; NOAEL derived from an OECD Guideline 90-day oral toxicity study. No significant effects were observed in rats dosed with 300 mg/kg/day. |
|
Quality of whole database |
2 |
The available data on DIDS and good read-across compounds are adequate to derive the DNEL.DIDS is a simple diester that rapidly hydrolyses to a fatty acid and alcohol (as also suggested by the results of a ready biodegradability test). Its toxicological characteristics are well understood and accepted to be of low concern. Properties can therefore be predicted with reasonable confidence. |
|
Other AFs |
1 |
None considered necessary. |
|
Overall AF for worker |
50 |
Worker (light activity) -DNEL (long-term for inhalation route-systemic)
=392.6 mg/m3/ 50 =7.9 mg/m3
Dermal DNEL (repeated dose toxicity)
Dose descriptor
There are no data available in humans or laboratory animals relating to the toxicity of DIDS following repeated dermal exposures. However, the repeated dose toxicity of DIDS has been investigated in an OECD Guideline 90-day oral toxicity study in rats. Kidney toxicity was seen in male rats receiving 1000 mg/kg/day in an OECD Guideline 90-day toxicity study on DIDS, but not female rats. No significant effects were seen in either sex receiving 300 mg/kg/day DIDS.
Mode-of-action
DIDS is considered to have only threshold effects, as there is no evidence that it possesses genotoxic potential. The lesion seen in male rat kidneys has the characteristics ofhyaline dropletnephropathy is most likely due to ana2mglobulin mode of action and is not relevant for humans. Immunohistopathology has not been carried out on the male rat kidney tissues so thea2mglobulin mode of action cannot be confirmed. As a consequence, the most conservative approach to risk assessment has been adopted by selecting the NOAEL in male rats as the starting point (300 mg/kg/day)
Modification of starting point
As no relevant data on effects of repeated dermal exposure to DIDS in humans or laboratory animals are available, route-to-route extrapolation to calculate a dermal DNEL from a 90-day oral toxicity study was considered a suitable alternative.
No data are available on the degree of absorption of DIDS. It is assumed that the degree of absorption by the oral is 100% and is 10% by the dermal route in both rats and humans. The starting point for the dermal NOAEL for DIDS in humans is therefore considered to be:
300 x 100/10 = 3,000 mg/kg/day.
ECHA AFs for workers – dermal DNEL (repeated dose toxicity)
Uncertainty |
AF |
Justification for AF |
Interspecies differences
|
4 |
Default ECHA AF for rat for toxicokinetic differences in metabolic rate (allometric scaling) |
2.5 |
Default ECHA AF for remaining toxicokinetic differences (not related to metabolic rate) and toxicodynamic differences |
|
Intraspecies differences |
5 |
Default ECHA AF for (healthy) worker |
Differences in duration of exposure |
2 |
Default ECHA AF for sub chronic (90-day) to chronic extrapolation |
Dose response and endpoint specific/severity issues |
1 |
Default ECHA AF; NOAEL from an OECD Guideline 90-day oral toxicity study. No significant effects were observed in rats dosed with 300 mg/kg/day. |
Quality of the whole database |
2 |
The available data on DIDS and good read-across compounds are adequate to derive the DNEL. DIDS is, a simple diester that rapidly hydrolyses to a fatty acid and alcohol (as also suggested by the results of a ready biodegradability test). Its toxicological characteristics are well understood and accepted to be of low concern. Properties can therefore be predicted with reasonable confidence. |
Other AFs |
1 |
None considered necessary. |
Overall AF for worker |
200 |
|
Worker-DNEL (long-term for dermal route-systemic) = 3,000 mg/kg bw/day / 200 = 15.00 mg/kg bw/day
Genotoxicity
No test data are available on the genotoxic effects of DIDS. DIDA and DEHS did not demonstrate mutagenic activity in reliable bacterial reverse mutation assays. Equivocal evidence of mutagenicity was detected in a mouse lymphoma assay on DIDA at concentrations associated with cytotoxicity. Similarly, a chromosome aberration assay on human lymphocytes treated with DIDA also gave an equivocal result at cytotoxic concentrations. Noin vivoresults were available on DIDS, DIDA or DOS/DEHS. Overall, no convincing evidence of genotoxic activity was seen or is expected, as such DIDS does not warrant classification as mutagenic. Consequently, no worker-DN(M)ELs for genotoxicity have been calculated.
Carcinogenicity
No standard carcinogenicity studies are available on DIDS. Chronic testing is not a requirement at this tonnage level (100-1000 tpa). Based on structural considerations, no carcinogenic activity is expected for DIDS and it is not classified as genotoxic. Limited reassurance can be gleaned from the lack of carcinogenic activity seen in rats fed DOS at about 10 mg/kg bw/day in the diet for 19 months. The absence of carcinogenicity at this low dose indicates that DOS is not a potent carcinogen.
Presumably, any chronic DNEL should also be protective against carcinogenic effects, given that repeated dose testing (an OECD Guideline 90-day oral toxicity study with DIDS) produced no apparent pre-carcinogenic effects. Consequently, no worker-DN(M)ELs for carcinogenicity have been calculated.
Reproductive toxicity (fertility impairment and developmental toxicity)
The results of an OECD Guideline 90-day oral toxicity study (with detailed examination of the reproductive organs) and an OECD Guideline prenatal developmental toxicity study are available. No adverse effects on developmental toxicity endpoints were seen in the prenatal developmental toxicity study and no adverse histopathology was observed in the reproductive organs of either sex in the 90-day oral toxicity study. As a consequence, it was considered unnecessary to derive DNELs for effects on fertility or development.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 3.9 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- By inhalation
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 100
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 392.6 mg/m³
- Explanation for the modification of the dose descriptor starting point:
- Route to route extrapolation was necessary.
- AF for dose response relationship:
- 1
- Justification:
- There are no data available in humans or laboratory animals relating to repeated inhalation exposure of DIDS.
Kidney toxicity was seen in male rats receiving 1000 mg/kg/day in an OECD Guideline 90-day toxicity study on DIDS, but not female rats. No significant effects were seen in either sex receiving 300 mg/kg/day DIDS. - AF for differences in duration of exposure:
- 2
- Justification:
- Default ECHA AF for subchronic (90-day) to chronic extrapolation.
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Default ECHA AF for rat for toxicokinetic differences in metabolic rate (allometric scaling) not applicable.
- AF for other interspecies differences:
- 2.5
- Justification:
- Default ECHA AF for remaining toxicokinetic differences (not related to metabolic rate) and toxicodynamic differences.
- AF for intraspecies differences:
- 10
- Justification:
- Default ECHA AF for general population.
- AF for the quality of the whole database:
- 2
- Justification:
- The available data on DIDS and good read-across compounds are adequate to derive the DNEL.. DIDS is a simple diester that rapidly hydrolyses to a fatty acid and alcohol (as also suggested by the results of a ready biodegradability test). Its toxicological characteristics are well understood and accepted to be of low concern. Properties can therefore be predicted with reasonable confidence.)
- AF for remaining uncertainties:
- 1
- Justification:
- No further uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 7.5 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- By inhalation
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 400
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 3 000 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- As no data on effects of repeated dermal exposure to DIDS in humans or laboratory animals are available, route-to-route extrapolation to calculate a DNEL for such effects from repeated dose oral toxicity study was considered a suitable alternative.
- AF for dose response relationship:
- 1
- Justification:
- Default ECHA AF; NOAEL from an OECD Guideline 90-day oral toxicity study. No significant effects were observed in rats dosed with 300 mg/kg/day.
- AF for differences in duration of exposure:
- 2
- Justification:
- Default ECHA AF for subchronic (90-day) to chronic extrapolation.
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- Default ECHA AF for rat for toxicokinetic differences in metabolic rate (allometric scaling).
- AF for other interspecies differences:
- 2.5
- Justification:
- Default ECHA AF for remaining toxicokinetic differences (not related to metabolic rate) and toxicodynamic differences.
- AF for intraspecies differences:
- 10
- Justification:
- Default ECHA AF for general population.
- AF for the quality of the whole database:
- 2
- Justification:
- The available data on DIDS and good read-across compounds are adequate to derive the DNEL. DIDS is a simple diester that rapidly hydrolyses to a fatty acid and alcohol (as also suggested by the results of a ready biodegradability test). Its toxicological characteristics are well understood and accepted to be of low concern. Properties can therefore be predicted with reasonable confidence.
- AF for remaining uncertainties:
- 1
- Justification:
- No further uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.8 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 400
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 300 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- No modification of the starting point is necessary.
- AF for dose response relationship:
- 1
- Justification:
- Default ECHA AF; NOAEL from an OECD Guideline 90-day oral toxicity study. No significant effects were observed in rats dosed with 300 mg/kg/day.
- AF for differences in duration of exposure:
- 8
- Justification:
- AF for subacute (14-day) to chronic extrapolation.
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- Default ECHA AF for rat for toxicokinetic differences in metabolic rate (allometric scaling).
- AF for other interspecies differences:
- 2.5
- Justification:
- Default ECHA AF for remaining toxicokinetic differences (not related to metabolic rate) and toxicodynamic differences.
- AF for intraspecies differences:
- 10
- Justification:
- Default ECHA AF for general population.
- AF for the quality of the whole database:
- 2
- Justification:
- The available data on DIDS and good read-across compounds are adequate to derive the DNEL. DIDS is a simple diester that rapidly hydrolyses to a fatty acid and alcohol (as also suggested by the results of a ready biodegradability test). Its toxicological characteristics are well understood and accepted to be of low concern. Properties can therefore be predicted with reasonable confidence.
- AF for remaining uncertainties:
- 1
- Justification:
- Limited study performed on a very closely-related read-across compound (DIDA), and very briefly reported in the secondary literature.
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
Discussion
Acute toxicity
As explained in the worker DNEL section above, no acute hazard has been identified for DIDS, therefore a DNEL for acute toxicity is unnecessary as the long-term systemic general population DNEL will be sufficient to ensure that adverse effects do not occur.
Irritation/corrosivity
Based on the available data, DIDS would not be classified as a skin, eye or respiratory tract irritant. Consequently, no general population-DNELs for irritation/corrosivity have been calculated.
Sensitisation
Based on the available data, DIDS would not be classified as a skin or respiratory sensitiser and therefore, no general population-DNELs for skin or respiratory sensitisation have been calculated.
Oral DNEL (repeated dose toxicity)
Dose descriptor
Kidney toxicity was seen in male rats receiving 1000 mg/kg/day in an OECD Guideline 90-day toxicity study on DIDS, but not female rats. No significant effects were seen in either sex receiving 300 mg/kg/day DIDS.
Mode-of-action
DIDS is considered to have only threshold effects, as there is no convincing evidence that it possesses genotoxic potential. The lesion seen in male rat kidneys has the characteristics ofhyaline dropletnephropathy is most likely due to ana2mglobulin mode of action and is not relevant for humans. Immunohistopathology has not been carried out on the male rat kidney tissues so thea2mglobulin mode of action cannot be confirmed. As a consequence, the most conservative approach to risk assessment has been adopted by selecting the NOAEL in male rats as the starting point (300 mg/kg/day)
Modification of starting point
In the absence of any data to the contrary, the same bioavailability is assumed for humans and laboratory animals. No modification of the starting point is necessary.
ECHA AFs for general population – oral DNEL (repeated dose toxicity)
Uncertainty |
AF |
Justification for AF |
|
Interspecies differences
|
4 |
Default ECHA AF for rat for toxicokinetic differences in metabolic rate (allometric scaling) |
|
2.5 |
Default ECHA AF for remaining toxicokinetic differences (not related to metabolic rate) and toxicodynamic differences |
||
Intraspecies differences |
10 |
Default ECHA AF for general population |
|
Differences in duration of exposure |
2 |
Default ECHA AF for sub chronic (90-day) to chronic extrapolation |
|
Dose response and endpoint specific/severity issues |
1 |
Default ECHA AF; NOAEL from an OECD Guideline 90-day oral toxicity study. No significant effects were observed in rats dosed with 300 mg/kg/day. |
|
Quality of whole database |
2 |
The available data on DIDS and good read-across compounds are adequate to derive the DNEL. DIDS is a simple diester that rapidly hydrolyses to a fatty acid and alcohol (as also suggested by the results of a ready biodegradability test). Its toxicological characteristics are well understood and accepted to be of low concern. Properties can therefore be predicted with reasonable confidence. |
|
Other AFs |
1 |
None considered necessary. |
|
Overall AF for general population |
400 |
|
General population-DNEL (long-term for oral route-systemic)= 300 mg/kg bw/day / 400 =0.8 mg/kg bw/day
Inhalation DNEL (repeated dose toxicity)
Dose descriptor
Kidney toxicity was seen in male rats receiving 1000 mg/kg/day in an OECD Guideline 90-day toxicity study on DIDS, but not female rats. No significant effects were seen in either sex receiving 300 mg/kg/day DIDS.
Mode-of-action
DIDS is considered to have only threshold effects, as there is no convincing evidence that it possesses genotoxic potential. The lesion seen in male rat kidneys has the characteristics ofhyaline dropletnephropathy is most likely due to ana2mglobulin mode of action and is not relevant for humans. Immunohistopathology has not been carried out on the male rat kidney tissues so thea2mglobulin mode of action cannot be confirmed. As a consequence, the most conservative approach to risk assessment has been adopted by selecting the NOAEL in male rats as the starting point (300 mg/kg/day)
Modification of starting point
The corrected inhalation NOAEC for DIDS =
300 * (1/ sRV(a) *ABS oral-rat / ABS inhal-human (b) * 0.67 (c))
Where: (a) Standard respiratory volume (sRV) rat = 0.384 m3/kg
(b) For oral route based on toxicokinetics data on DOA (EC number: 203-090-1 CAS number: 103-23-1)
ABS oral-rat = 75 % and ABS inhal-human = 100 %
(c) correction for worker respiratory volume (conservative default for route to route)
= 300*1/0.384*75/100*0.67 = 392.6 mg/m3
ECHA AFs for general population – inhalation DNEL (repeated dose toxicity)
Uncertainty |
AF |
Justification for AF |
||
Interspecies differences
|
1 |
Default ECHA AF for rat for toxicokinetic differences in metabolic rate (allometric scaling) not applicable. |
||
2.5 |
Default ECHA AF for remaining toxicokinetic differences (not related to metabolic rate) and toxicodynamic differences. |
|||
Intraspecies differences |
10 |
Default ECHA AF for general population. |
||
Differences in duration of exposure |
2 |
Default ECHA AF for subchronic (90-day) to chronic extrapolation. |
||
Dose response and endpoint specific/severity issues |
1 |
Default ECHA AF; NOAEL from an OECD Guideline 90-day oral toxicity study. No significant effects were observed in rats dosed with 300 mg/kg/day. |
||
Quality of whole database |
2 |
No human health effects data are available on DIDS, and testing is proposed. The available data on good read-across compounds are generally limited. DIDS is, however, a simple diester that rapidly hydrolyses to a fatty acid and alcohol (as also suggested by the results of a ready biodegradability test). Its toxicological characteristics are well understood and accepted to be of low concern. Properties can therefore be predicted with reasonable confidence. |
||
Other AFs |
1 |
Limited study performed on a closely-related read-across compound (DEHS, considered a worst-case surrogate for DIDS), and very briefly reported in the secondary literature. |
||
Overall AF for general population |
100 |
|
General population-DNEL (long-term for inhalation route-systemic) = 392.6 mg/m3/ 100 =3.9 mg/m3
Dermal DNEL (repeated dose toxicity)
Dose descriptor
There are no data available in humans or laboratory animals relating to the toxicity of DIDS following repeated dermal exposures. However, the repeated dose toxicity of DIDS has been investigated in an OECD Guideline 90-day oral toxicity study in rats. Kidney toxicity was seen in male rats receiving 1000 mg/kg/day in an OECD Guideline 90-day toxicity study on DIDS, but not female rats. No significant effects were seen in either sex receiving 300 mg/kg/day DIDS.
Mode-of-action
DIDS is considered to have only threshold effects, as there is no evidence that it possesses genotoxic potential. The lesion seen in male rat kidneys has the characteristics ofhyaline dropletnephropathy is most likely due to ana2mglobulin mode of action and is not relevant for humans. Immunohistopathology has not been carried out on the male rat kidney tissues so thea2mglobulin mode of action cannot be confirmed. As a consequence, the most conservative approach to risk assessment has been adopted by selecting the NOAEL in male rats as the starting point (300 mg/kg/day)
Modification of starting point
As no relevant data on effects of repeated dermal exposure to DIDS in humans or laboratory animals are available, route-to-route extrapolation to calculate a dermal DNEL from a 90-day oral toxicity study was considered a suitable alternative.
No data are available on the degree of absorption of DIDS. It is assumed that the degree of absorption by the oral is 100% and is 10% by the dermal route in both rats and humans. The starting point for the dermal NOAEL for DIDS in humans is therefore considered to be:
300 x 100/10 = 3,000 mg/kg/day. ECHA AFs for general population – dermal DNEL (repeated dose toxicity)
Uncertainty |
AF |
Justification for AF |
|
Interspecies differences
|
4 |
Default ECHA AF for rat for toxicokinetic differences in metabolic rate (allometric scaling) |
|
2.5 |
Default ECHA AF for remaining toxicokinetic differences (not related to metabolic rate) and toxicodynamic differences |
||
Intraspecies differences |
10 |
Default ECHA AF for general population |
|
Differences in duration of exposure |
2 |
Default ECHA AF for sub-chronic (90-day) to chronic extrapolation |
|
Dose response and endpoint specific/severity issues |
1 |
Default ECHA AF; NOAEL from an OECD Guideline 90-day oral toxicity study. No significant effects were observed in rats dosed with 300 mg/kg/day. |
|
Quality of the whole database |
2 |
No human health effects data are available on DIDS, and testing is proposed. The available data on good read-across compounds are generally limited. DIDS is, however, a simple diester that rapidly hydrolyses to a fatty acid and alcohol (as also suggested by the results of a ready biodegradability test). Its toxicological characteristics are well understood and accepted to be of low concern. Properties can therefore be predicted with reasonable confidence. |
|
Other AFs |
1 |
Limited study performed on a closely-related read-across compound (DEHS, considered a worst-case surrogate for DIDS), and very briefly reported in the secondary literature. |
|
Overall AF for general population |
400 |
|
General population DNEL (long-term for dermal route-systemic) = 3,000 mg/kg bw/day / 400 = 7.5 mg/kg bw/day
Genotoxicity
No general population DN(M)ELs for genotoxicity have been calculated as DIDS and its read-across compounds DIDA and DOS/DEHS have displayed no convincing evidence of genotoxic activity in a range ofin vitrotests.
Carcinogenicity
No general population DN(M)ELs for carcinogenicity have been calculated as no carcinogenic activity is expected for DIDS.
Reproductive toxicity (fertility impairment and developmental toxicity)
The results of an OECD Guideline 90-day oral toxicity study (with detailed examination of the reproductive organs) and an OECD Guideline prenatal developmental toxicity study are available. No adverse effects on developmental toxicity endpoints were seen in the prenatal developmental toxicity study and no adverse histopathology was observed in the reproductive organs of either sex in the 90-day oral toxicity study. As a consequence, it was considered unnecessary to derive DNELs for effects on fertility or development.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.